Endo Sees Regulatory Setting For Opana ER As "A Moving Target"
This article was originally published in Pharmaceutical Approvals Monthly
The “complete response” letter for the crush-resistant formulation of Endo Pharmaceuticals’ chronic pain drug Opana ER (oxymorphone) is not surprising, given that FDA has yet to settle on a risk management approach for extended-release opioids.
You may also be interested in...
ProStrakan's Abstral is first use of the REMS templates; the agency expects sponsors of similar immediate-release transmucosal products to follow suit and share a REMS implementation system.
FDA wants a bigger stick for product-specific Risk Evaluation and Mitigation Strategy negotiations, if for no other reason than to end the talks and make the final decision.
Sale announced concurrently with filing of NDA for new crush-proof formulation of the opioid Opana ER.